Tirzepatide.
About Tirzepatide
Tirzepatide is among the compounds studied in metabolic and weight-regulation research. Tirzepatide simultaneously activates GLP-1 and GIP receptors and shows a so-called “biased agonism” profile, which studies associate with improved tolerability compared to pure GLP-1 agonists.
Research Application
Studied in metabolic research as a dual receptor agonist; its described “biased agonism” profile is associated with improved tolerability compared to pure GLP-1 agonists. FDA approved for diabetes and weight management.
Important to know
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
Research Overview
A growing number of preclinical and clinical studies exist for metabolic peptides, though the volume varies significantly by substance.
- Jastreboff AM, et al. NEJM. 2022;387(3):205–216.
- Aronne LJ, et al. NEJM. 2025;393(1):26–36. PMID 40353578
- Frias JP, et al. NEJM. 2021;385(6):503–515.
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
Question about Tirzepatide?
We reply personally – via email or Telegram.